JW CreaGene holds the rights for the dendritic cell technology used in development of cancer treatment and drug delivery technology (CTP: Cytoplasmic Transduction Peptide) that can effectively deliver polymer substances to the cells as the key foundation technologies. Moreover, the company is developing dendritic cell therapeutics aimed at enhancing immunity and immune tolerance by applying the relevant technologies.